CURRICULUM VITAE
Subramaniam Malarkannan PhD
Subramaniam Malarkannan PhD
Professor
Department of Medicine
Division of Medicine Hematology Oncology
Department of Medicine
Division of Medicine Hematology Oncology
OFFICE ADDRESS: |
8727 Watertown Plank Road |
Milwaukee, WI 53226 |
EDUCATION: |
1980 - 1983 B.Sc., The American College Madurai, Madurai, Tamil Nadu |
1983 BS, The American College, Madurai, India |
1983 - 1985 M.Sc., The American College Madurai, Madurai, Tamil Nadu |
1985 - 1987 M.Phil., Madurai Kamaraj University, Madurai, Tamil Nadu |
1985 MS, The American College, Madurai, India |
1987 M. Phil, Madurai Kamaraj University, Madurai, India |
1987 - 1992 Ph.D. in human T cell biology, Department of Immunology, Graduate student in the lab of Prof. Veerappan R Muthukkaruppan Ph.D., Professor of Immunology |
01/1991 - 12/1992 Visiting Predoctoral Fellow in the lab of Prof. Daniel C Hoessli MD, Department of Pathology, University of Geneva, Geneva |
06/1992 - 06/1998 Postdoctoral Fellow in the lab of Prof. Nilabh Shastri, Ph.D., Department of Molecular and Cell Biology, Division of Immunology |
1992 Ph. D, Madurai Kamaraj University, Madurai, India |
07/1998 - 02/2000 Associate Specialist in the lab of Prof. Nilabh Shastri, Ph.D., University of California at Berkeley, CA. Molecular mechanism of cr |
1) Transcriptional Regulation of Human NK cell development: GATA2 is an essential transcription fact, two transactivation domains, and one negative regulatory domain. The specific loss of the CD56bright NK cell population is a salient feature in GATA2T354M patients, with or without reduced CD56di |
2) Transcriptional regulation involved with memory NK cells. The developmental origins and molecular, NKG2C+ NK cells mount a response akin to adaptive immunity and establish a reservoir of long-lived memory cells in HCMV+ individuals. The origins by which memory NKG2C+ NK cells are maintained remain, we used human spleens to investigate the transcriptional signatures and the developmental origins of memory NKG2C+ NK cells. We discover that the human spleen houses a distinct subset of memory NKG2CH, memory NKG2CHi NK cells expand |
3) Generation and functions of NKRegs during pediatric GvHD. Allogeneic hematopoietic stem cell tran, chronic graft-versus-host disease (GvHD) remains a leading cause of late morbidity and mortality. Distinct from acute GvHD (aGvHD), chronic GvHD (cGvHD) involves multiple cell types, including T cells |
4) Genomic and Immunological Predisposition to CD20/CD19 Bi-specific CAR T cell Therapy: Bi-specific, 4-1BB-CD3zLV20.19)-transduced T cell therapy provides a revolutionary approach to treat relapsed and refractory B cell malignancies. Yet a significant number of patients relapse or have only partial r, leveraging an ongoing Phase I/II clinical trial, we performed scRNA and bulk RN |
5) Haploidentical-NK cell therapy: Working with a pediatric bone marrow transplant physician, Dr. Monica Thakar MD, (currently at) Seattle Children/Fred Hutch, we were able to get FDA approv |
POSTGRADUATE TRAINING: |
RESEARCH INTEREST: |
codons mediated translation initiations |
POSTGRADUATE TRAINING AND FELLOWSHIP APPOINTMENTS: |
01/1991 - 12/1992 Visiting Fellow, Department of Pathology, University of Geneva, Geneva, Switzerland |
06/1992 - 06/1998 Postdoctoral Fellow, Department of Molecular and Cell Biology, Division of Immunology, University of California, Berkeley, CA |
07/1998 - 02/2000 Associate Specialist, Molecular mechanism of cryptic epitope generation, Division of Immunology, University of California, Berkeley, CA |
FACULTY APPOINTMENTS: |
3 - 2015 Nan Gardetto Endowed Chair for Immunotherapy, Blood Research |
3 - 2000 11/2006 Associate Investigator (Secondary), Blood Research Institute, Blood |
7 - 2014 Division of, Professor of Medicine-Hematology & Oncology (Primary) |
7 - 2007 06/2014 Associate Professor of Medicine (Primary), Department of Medicine, Division of Hematology and Oncology, MCW, Milwaukee, WI |
9 - 2014 Professor of Pediatrics (Secondary), Department of Pediatrics, MCW |
03/2000 - 06/2007 Assistant Professor of Medicine, Department of Medicine, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI 53226 |
03/2000 - 2006 Associate Investigator, Blood Research Institute, Laboratory of Molecular Immunology, Blood Center of Wisconsin, Milwaukee, WI 53226 |
03/2000 - 06/2006 Division of Hematology and, Assistant Professor of Medicine (Primary) |
12/2002 - 06/2006 Assistant Professor, Department of Microbiology and Immunology |
12/2006 - Present Investigator, Blood Research Institute, Laboratory of Molecular Immunology, Blood Center of Wisconsin, Milwaukee, WI 53226 |
12/2006 - 02/2014 Investigator (Secondary), Blood Research Institute, Blood Center of |
07/01/2007 - 06/31/2014 Associate Professor of Medicine, Department of Medicine, Hematology and Oncology, MCW |
02/14/2014 - Present Senior Investigator, Blood Research Institute |
02/2014 - Present Senior Investigator, Blood Research Institute, Blood Center of Wisconsin |
03/01/2014 - Present Executive Council Member, Drug Development and Repurposing Initiative, CTSI, MCW |
03/2014 - Present Executive Council Member, Drug Development and Repurposing Initiative (DDRI), SE WI Clinical and Translational Science Institute. |
07/01/2014 - Present Professor of Medicine, Department of Medicine, MCW |
07/01/2014 - Present Professor of Microbiology and Molecular Genetics, MCW |
09/01/2014 - Present Professor of Pediatrics, Pediatrics, Hematology, Oncology and Transplantation, MCW |
Milwaukee, WI |
Institute, Blood Center of Wisconsin, Milwaukee, WI |
Center of Wisconsin, Milwaukee, WI |
Wisconsin, Milwaukee, WI |
of Microbiology and Immunology, MCW, Milwaukee, WI |
Oncology, Department of Medicine, MCW, Milwaukee, WI |
Milwaukee, WI |
Medical College of Wisconsin, Milwaukee, WI |
Hematology & Oncology, Department of Medicine, MCW, Milwaukee, WI 07-2014- Professor of Microbiology and Immunology (Secondary), Department |
ADMINISTRATIVE APPOINTMENTS: |
06/2000 - Present Member, Cancer Center Grants Committee, MCW, Milwaukee, WI |
06/2002 - 2016 Member, Seminar Committee, BRI, Milwaukee, WI |
08/2004 - 2007 Member, Radiation Safety Committee, BRI, Milwaukee, WI |
2007 - 2014 Chair, Radiation Safety Committee, Blood Research Institute, Milwaukee, WI 06/2014-2017 Coordinator, Monthly Research Meeting, Department of Medicine, Division of HemOnc, MCW |
03/2014 - Present Standing Member, Clinical Research Grant Committee, Cancer Center |
06/2014 - Present Coordinator, Basic Science, High-Risk Hematological Malignancy Program |
09/2018 - 2021 Associate Director, Stimulating Access to Research in Residency (StARR) Program (HL143561), MCW |
Medical College of Wisconsin Milwaukee, WI. |
(HRHM), MACC Fund, Department of Pediatrics, MCW |
EDUCATIONAL ADMINISTRATIVE APPOINTMENTS: |
1993 - 2000 Mentor,, Undergraduate students in the Division of Immunology |
2001 - Present Teaching faculty, Topics in Microbiology and Immunology, Medical |
2001 - Present Teaching faculty, Graduate courses in Immunology (Tumor |
2001 - Present Teaching faculty, Medical Microbiology, Medical College of |
2001 - Present Teaching faculty, Research conferences for Medical Students |
2001 - Present Mentor, Honor's Thesis program in Immunology for Undergraduate |
2002 - Present Mentor, Minority Students Summer Research Program, Medical |
2004 - Present Mentor, SPUR Program, Medical College of Wisconsin |
2013 - 2019 Member, IDP Graduate Students' Admissions Committee |
2020 - Present Member, Admissions Committee - Medical Scientist Training Program (MD-PhD students), Medical College of Wisconsin, Milwaukee, WI |
Department of Microbiology and Immunology, Medical College of |
Milwaukee, WI |
Wisconsin, Milwaukee, WI. |
Representative, Medical College of Wisconsin, Milwaukee, WI |
Students; University of Wisconsin, Milwaukee, WI |
College of Wisconsin, Milwaukee, WI |
Department of Molecular and Cell Biology, UC Berkeley. |
Immunology, Cell signaling, Developmental Immunology & |
Wisconsin, Milwaukee, WI (MD Students) |
Department of Medicine, Medical College of Wisconsin, Milwaukee, WI |
College of Wisconsin, Milwaukee, WI (MD/ Ph.D. students) |
Advanced Immunology classes, Signaling in Immune cells) |
AWARDS AND HONORS: |
1985 Distinction and second rank in M. Sc in the class of 1985 |
1985 - Present Distinction and Second Rank in M. Sc in the class of 1985 |
1986 - 1990 Junior and Senior Research Fellow of Council of Scientific and |
1986 Distinction in M. Phil in the class of 1986 |
1986 - 1990 Junior and Senior Research Fellow of Council of Scientific and Industrial Research, Government of India |
1986 - Present Distinction in M. Phil in the class of 1986 |
1990 - 1991 Senior Graduate Fellow, Department of Science and Technology, Government of India |
1990 - 1991 Senior Graduate Fellow, Department of Science and Technology |
1991 - 1992 Postgraduate Fellow, Indo‐Swiss Collaboration in Biotechnology, ETH, and Zurich, Switzerland |
1991 - 1992 Postgraduate Fellow, Indo-Swiss Collaboration in Biotechnology, ETH |
1992 - 1993 Postdoctoral Fellow, Cancer Research Coordination Committee |
1992 - 1993 Postdoctoral Fellow, Cancer Research Coordination Committee, University of California at Berkeley |
1992 - 1995 Postdoctoral Fellows, World Health Organization, Geneva |
1992 - 1995 Postdoctoral Fellow, WHO, Geneva, Switzerland (declined) |
1993 - 1995 Postdoctoral Fellow, American Cancer Society (California Chapter) |
1993 - 1995 Postdoctoral Fellow, American Cancer Society (California Chapter) |
1997 - 1998 Postdoctoral Fellow, Cancer Research Coordination Committee, University of California at Berkeley |
1997 - 1998 Postdoctoral Fellow, Cancer Research Coordination Committee |
2002 - 2004 Young Investigator Award, American Society for Blood and Marrow Transplantation, National Chapter, Atlanta, GA, USA |
2002 - 2007 ACS Research Scholar Award, American Cancer Society (National Chapter) |
2002 - 2007 International ROTRF Scholar Award, Roche Organ Transplantation Research Foundation, Roche Inc. Switzerland |
2002 - 2007 International ROTRF Scholar Award, Roche Organ Transplantation |
2002 - 2004 Young Investigator Award; American Society for Blood and Marrow |
2002 - 2007 ACS Research Scholar Award, American Cancer Society (National |
2007 - 2009 Adhoc Member, Innate Immunity and Inflammation Study Section, NIAID. NIH |
2009 - 2012 Full Member, Innate Immunity and Inflammation Study Section, NIAID |
2009 - Present Full Member, Innate Immunity and Inflammation Study Section, NIAID, NIH |
09/01/2013 - 08/31/2014 Springboard Award, Alex Lemonade Stand Foundation |
2014 - Present Michael J Dunn Award for Research Excellence at the Medical College of |
2015 - Present Gardetto Endowed Chair for Immunology and Immunotherapy. Blood Research |
2016 - Present Outstanding Mentor of Graduate School (2015-16), Medical College of |
2023 - Present Outstanding Mentor of Graduate School (2022-23), Medical College of |
University of California at Berkeley |
Research Foundation, Roche Inc. Switzerland |
University of California at Berkeley |
Chapter) |
Switzerland (declined). |
NIH |
Transplantation, National Chapter, Atlanta, GA, USA |
Wisconsin |
Government of India |
Institute, BloodCenter of Wisconsin |
Industrial Research, Government of India |
Wisconsin |
Wisconsin |
and Zurich, Switzerland |
MEMBERSHIPS IN HONORARY AND PROFESSIONAL SOCIETIES: |
1986 - 1992 The Indian Immunology Society |
1986 - 1992 The Indian Immunology Society (Member) |
1991 - 1992 European Network of Immunology Institutes (Member) |
1991 - 1992 European Network of Immunology Institutes |
1992 - Present The Association for the Advancement of Science |
1992 - Present The Association for the Advancement of Science (Member) |
2001 - Present American Association of Immunologists (Member) |
2001 - Present American Association of Immunologists |
2020 - Present American Society for Hematology |
EDITORSHIPS/EDITORIAL BOARDS/JOURNAL REVIEWS: |
Editorship |
2006 Seminars in Immunology |
2006 Vol 18:3, titled ‘NK Cell Development and Function: Missing‐Self Revisited’ |
Journal Review |
2000 Journal of Immunology |
2001 Blood |
2004 Biology of Blood and Marrow Transplantation |
2006 Bone Marrow Transplantation |
2007 Molecular Immunology |
2008 Innate Immunity |
2008 Cancer Gene Therapy |
2009 Nature‐Signaling Gateway |
2009 Chronobiology International |
2009 PloS Biology, PloSOne |
2010 PNAS |
LOCAL/REGIONAL APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
06/2002 - Present Member, Seminar Committee, Blood Research Institute |
06/2004 - Present Member, Cancer Center Grants Committee, Medical College of Wisconsin |
08/2004 - 2007 Member, Radiation Safety Committee, Blood Research Institute |
2004 - Present Member, Cancer Center Grants Committee, Medical College of Wisconsin, Milwaukee, WI |
08/2007 - Present Chair, Radiation Safety Committee, Blood Research Institute |
09/2010 - Present Member, External Advisory Committee, BEST Grant, STEM Program of the NSF, Milwaukee Area Technical College |
09/2010 - Present Member, External Advisory Committee, BEST Grant, STEM Program of the |
06/2012 - Present Member, Clinical and Translational Science Institute (CTSI), MCW. |
08/2013 - Present Member, Grants Review Committee, CTSI, MCW. |
03/2014 - Present Standing Member, Clinical Research Seed Grant Committee, MCW Cancer Center. |
03/2014 - Present Member, Executive Council, Drug Development and Repurposing Initiative, CTSI, MCW. |
06/2014 - Present Coordinator, Cellular Immunotherapy Program, Campus-wide, MCW. |
06/2014 - Present Leader, Basic Science, High-Risk Hematological Malignancies Program of MACC Fund. |
08/2014 - Present Coordinator, Research Meetings, HemOnc Division, Dept Medicine, MCW. |
01/2015 - Present Member, Steering Committee, Training Grant (T32 in its 40-45 years), BRI, BCW. |
08/2016 - Present Member, Grants Review Committee, Advancing Healthier Wisconsin (AHW), MCW. |
10/2020 - Present Chair, Faculty Search Committee, Immuno-Oncology Initiative, MCW Cancer Center. |
10/2023 - Present Member, Faculty Search Committee, Center for Immunology, MCW. |
10/2023 - Present Co-Chair, Faculty Search Committee, Immunology Program, VBRI. |
10/2024 - Present Member, Program Leader Search Committee, Immunology Program, VBRI. |
02/2025 - Present Co-Chair, Faculty Search Committee, Immunology Program, VBRI (New Initiative). |
NSF, Milwaukee Area Technical College, Milwaukee, WI. |
NATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
2004 External Member, Grant Review Committee, Italian Society for Cancer Research, Italy |
2005 - 2006 Adhoc Reviewer, NIAID, Immune Regulation of Autoimmune disorders, NIH. |
2006 - Present Adhoc Reviewer, NIAID, Innate Immunity and Inflammation (III) Study |
2008 Full‐Member, NIAID‐Innate Immunity and Inflammation (III) Study Section, NIH |
2009 External Member, Grant Review Committee, Agency for Science, Technology and Research (A*STAR), Biomedical Research Council of the Govt. Singapore (BMRC), Extramural Program, Singapore |
2009 - 2012 Full-Member, NIAID, Innate Immunity and Inflammation (III) Study Section, NIH |
2010 External Member, Grant Review Committee, Infection and Immunity Board, UK Medical Research Council (MRC), Extramural Program, UK |
2011 - Present Adhoc Reviewer, Minority Biomedical Research Support, National Institute |
2012 - Present Adhoc Reviewer, NIAID, Innate Immunity and Inflammation (III) Study Section, NIH |
2013 - Present Adhoc Reviewer, NIAID, Innate Immunity and Inflammation (III) Study Section, NIH |
2014 - Present Adhoc Reviewer, NIAID, IMM-J81A AREA Grants Study Section, NIH |
2014 - Present Adhoc Reviewer, NIAID, F07-J20L Study Section, NIH |
2014 - Present Adhoc Reviewer, NIAID, ZRG IMM Study Section, NIH |
2014 - Present Adhoc Reviewer, NIAID, Innate Immunity and Inflammation (III) Study Section, NIH |
2015 - Present Adhoc Reviewer, NIAID, ZRG-IMM-F-08, NIH |
2015 - Present Adhoc Reviewer, NIAID, ZRG-IMM-F-02, NIH |
2015 - Present Adhoc Reviewer, NIAID, Innate Immunity and Inflammation (III) Study Section, NIH |
2016 - Present Chair, NIAID, ZRG IMM-F-02 Study Section, NIH |
2016 - Present Reviewer, NIGM, R35 Review Panel |
2016 - Present Adhoc Reviewer, NIAID, Innate Immunity and Inflammation (III) Study Section, NIH |
2016 - Present Adhoc Reviewer, LCMI, NIH |
2017 - Present Adhoc Reviewer, NIAID, Innate Immunity and Inflammation (III) Study Section, NIH |
2017 - Present Adhoc Reviewer, NIAID, ZRG-IMM-F-02, NIH |
2017 - Present Adhoc Reviewer, NIAID, ZRG-IMM-U-81, NIH |
2017 - Present Adhoc Reviewer, NIAID, ZRG-F07-U-20, NIH |
2018 - Present Chair, NIAID, ZRG1 IMM-F-02 Study Section, NIH |
2019 - Present Adhoc Reviewer, NIAID, Transplantation, Tolerance, and Tumor Immunology (TTT) Study Section, NIH |
2024 - Present Member, ASH Abstract Review Committee on Lymphocyte Biology |
2024 - Present Reviewer, SBIR, Advanced manufacturing of emerging autologous cell-based therapies Study section, NCI. |
2025 - Present Reviewer, ZRG1 CDPT-Z(08) Cancer Diagnostics, Prevention, and Treatments Study section, NCI. |
Section, NIH |
of General Medical Sciences, NIH. |
INTERNATIONAL ELECTED/APPOINTED LEADERSHIP AND COMMITTEE POSITIONS: |
2004 - Present External Member, Grant Review Committee, Italian Society for Cancer |
2009 - Present External Member, Grant Review Committee, Agency for Science, Technology, and |
2010 - Present External Member, Grant Review Committee, Infections and Immunity Board |
2013 - Present External Grant Reviewer, Swiss Cancer League, Bern, Switzerland |
2014 - Present External Grant Reviewer, National Science Centre, Poland. |
2017 - Present External Grant Reviewer, National Research Foundation (NRF), Government |
2018 - Present External Member, Grant Review Committee, Infections and Immunity Board |
2019 - Present External Member, Grant Review Committee, Breast Cancer Now, UK |
2019 - Present External Member, Grant Review Committee, University of Lyon, France |
2020 - Present External Member, Comprehensive Research Program, National Research Foundation, Government of Singapore. |
2020 - Present External Member, Grant Review Committee, Belgian Foundation Against Cancer, Belgium |
2021 - Present External Member, NMRC, Government of Singapore. |
2022 - Present External Referee Member, Marsden Fund, Royal Society Te Aparangi, Wellington, New Zealand |
2023 - Present External Member, Grant Review Committee, Infections and Immunity Board |
2024 - Present External Member, Worldwide Cancer Research, Edinburg UK |
UK Medical Research Council (MRC), Extramural Program, UK |
UK Medical Research Council (MRC), Extramural Program, UK |
of Singapore. |
UK Medical Research Council (MRC), Extramural Program, UK. |
Government of Singapore (BMRC) |
Research (A*STAR), Biomedical Research Council of the |
Research, Italy |
RESEARCH GRANTS/AWARDS/CONTRACTS/PROJECTS: | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
COMMITTEE SERVICE: |
Medical College of Wisconsin |
2004 Member, Cancer Center Grants Committee, Medical College of Wisconsin |
MCW TEACHING ACTIVITIES: |
Medical Student Education |
2001 - Present Teaching faculty, Topics in Microbiology and Immunology |
2001 - Present Teaching faculty, Research conferences for Medical Students, Dept Medicine |
2001 - Present Teaching faculty, Graduate course in Immunology, Dept Microbiology and Molecular Genetics |
2001 - Present Teaching faculty, Medical Microbiology |
2002 - Present Mentor, Minority Students Summer Research Program |
EXTRAMURAL TEACHING: |
Medical Student Education |
1993 - 2000 University of California - Berkeley, Mentor, Undergraduate students in the Div. Immunol., Molecular and Cell Biology |
2001 - Present University of Wisconsin, Milwaukee, Mentor, Honor’s Thesis program in Immunology for undergraduate students |
MCW STUDENTS, FACULTY, RESIDENTS AND CLINICAL/RESEARCH FELLOWS MENTORED: |
Graduate Students |
PhD Students Advised |
07/01/2013 - Present Alex Abel, MCW |
07/01/2014 - Present Zachary Gerbec, MCW |
07/01/2014 - Present Kate Dixon, MCW |
Clinical/Research Fellows |
2002 - 2004 Angela Timler, Department of Microbiology, Medical College of Wisconsin |
EXTRAMURAL STUDENTS, FACULTY, RESIDENTS, AND CLINICAL/RESEARCH FELLOWS MENTORED: |
Postdoctoral Researchers |
10/2001 - 2006 Dr Jeyarani Regunathan, Ph. D‐Postdoctoral Fellow |
05/2003 - Present Dr Aradhana Awasthi, Ph. D‐Postdoctoral Fellow |
11/2004 - 01/2005 Dr Netanya Spencer, MD Ph D‐Research Fellow |
07/2005 - 06/2006 Dr Snjezana Kutlesa, Ph. D‐Postdoctoral Fellow |
08/2005 - 2008 Dr Haiyan Chu, Ph. D‐Postdoctoral Fellow |
10/2006 - 2008 Dr Hailong Guo, Ph D‐ Postdoctoral Fellow |
10/2006 - 2007 Dr Tongbiao Zhao, Ph D‐Postdoctoral Fellow |
01/2007 - Present Dr Kamalakannan Rajasekaran, Ph D, Postdoctoral Fellow |
06/2007 - 2008 Dr Mathew Tinguely, MD, Postdoctoral Fellow |
11/2008 - Present Dr Pawan Kumar, Ph D, Postdoctoral Fellow |
02/2009 - Present Dr Ravikumar Lella, Ph D, Postdoctoral Fellow |
Clinical/Research Fellows |
2003 Eric Kohler, Rotation Student, MSTP Program, Medical Colege of Wisconsin |
2004 Sandya Govindarajan, Rotation Student, Dept Microbiology, Medical Colege of Wisconsin |
2006 - 2008 Mathew Tingley MD, Research Fellow, Department of Medicine, Medical Colege of Wisconsin |
2006 Tyce Kearl, Rotation Student, MSTP Program, Medical Colege of Wisconsin |
BIBLIOGRAPHY |
Refereed Journal Publications/Original Papers |
1. Fyn/ADAP via Carma1/Bcl10/Tak1 exclusively regulates inflammatory cytokine production. Rajasekaran K, Kumar P, Schuldt KM, Peterson EJ, Vanhaesebroeck B, Dixit V, Thakar MS and Malarkannan, S. (2013) Nature Immunology 14:1127-1136 |
2. IL-22: An Evolutionary Missing-Link Authenticating the Role of the Immune System in Tissue Regeneration. Kumar P, Palmer MJ, Thakar MS and Malarkannan S (2013) Journal of Cancer, 4: 57-65. |
3. Clinical Relevance of Natural Killer Cells Following Hematopoietic Stem Cell Transplantation. Palmer MJ, Rajasekaran K, Thakar MS and Malarkannan S (2013) Journal of Cancer, 4: 25-35. |
4. IQGAP1: A regulator of intracellular spacetime. Malarkannan S, Awasthi T, Rajasekaran K, and Thakar SM (2012) J Immunol-188:2057-2063 |
5. IL-22 from conventional NK cells are epithelial regenerative and inflammation protective during influenza infection. Kumar P, Rajasekaran K, Thakar MS, Ouyang W and Malarkannan S (2012) Mucosal Immunology, 6:69-82. |
6. Rajasekaran K, Chu H, Kumar P, Xiao Y, Tinguely M, Samarakoon A, Kim TW, Li X, Thakar MS, Zhang J, Malarkannan S. Transforming growth factor-beta-activated kinase 1 regulates natural killer cell-mediated cytotoxicity and cytokine production. J Biol Chem. 2011 Sep 09;286(36):31213-24. PMCID: PMC3173069 |
7. Kwun J, Malarkannan S, Burlingham WJ, Knechtle SJ. Primary vascularization of the graft determines the immunodominance of murine minor H antigens during organ transplantation. J Immunol. 2011 Oct 15;187(8):3997-4006. PMCID: PMC3357205 |
8. Rap1b facilitates NK cell functions via IQGAP1‐mediated signalosomes. Awasthi A, Samarakoon A, Chu H, Rajasekaran K, Quilliam L, Wodnicka M, White G, Malarkannan S. (2010) J Exp Med 207:1923‐1938 |
9. Functional dichotomy between NKG2D and CD28‐mediated co‐stimulation in human CD8+ T cells Rajasekaran K, Xiong V, Fong L, Gorski J, and Malarkannan S. (2010) EPup. PloSOne |
10. Evasion of natural killer cells by influenza virus Guo H, Kumar P, and Malarkannan S (2010) J Leuc Biol 89:1‐6 |
11. Murine NKG2D Ligands: "Double, double toil and trouble" Samarakoon A, Chu H, and Malarkannan S (2009) Molecular Immunology 46:1011‐1019 |
12. The Functional Impairment of Natural Killer cells During Influenza Virus Infection Guo H, Kumar P, Moran TM, Garcia‐Sastre A, Zhou Y and Malarkannan S (2009) 'Outstanding Observations'‐Immunology and Cell biology 87:579‐589 |
13. Recognition of allo‐peptide is governed by novel anchor imposition and limited variations in TCR contact residues Reinbold C and Malarkannan S (2008) Molecular Immunology 45:1318‐26 |
14. p85 subunit of PI3K plays a pivotal role in the cytokine generation in NK cells
Awasthi A, Chu H, Kutlesa S, Wang D, and Malarkannan S
(2008) Genes Immun. 9(6):522‐35 |
15. Rap1b Regulates B Cell Development, Homing, and T‐Dependent Humoral Immunity
Chu H, Awasthi A, White GC, Chrzanowska‐Wodnicka M, and Malarkannan S
(2008) J Immunol. 181(5):3373‐83 |
16. Impaired survival of peripheral T cells, disrupted NK/NKT cell development, and liver failure in mice
lacking gimap5
Schulteis RD, Chu H, Dai X, Chen Y, Edwards B, Haribhai B, Williams CB, Malarkannan S, Hessner MJ,
Glisic‐Milosavljevic S, Jana S, Kerschen EJ, Ghosh S, Wang D, Kwitek AE, Lernmark A, Gorski J, and
Weiler H
(2008) Blood 112:4905-14 |
17. The p110‐delta isoform of PI 3‐kinase plays a critical role in NK cell‐mediated tumor killing and viral
clearance
Guo H, Samarakoon A, Vanhaesebroeck B, and Malarkannan S
(2008) J Exp Med. 205(10):2419‐35 |
18. Bcl10 determines the NKG2D‐mediated signaling divergence of cytotoxicity and cytokine generation
in NK cells
Malarkannan S, Regunathan J, Chen Y, and Wang D
(2007) J Immunol. 179: 3752‐3762 |
19. Differential and non‐redundant roles of Phospholipase C2 and Phospholipase C1 in the terminal
maturation of NK cells
Regunathan J, Chen Y, Kutlesa S, Dai X, Bai L, Wen R, Wang D, and Malarkannan S
(2006) J Immunol. 177: 5365‐5376 |
20. NK cell Development and Function: Missing‐self revisited
Malarkannan S
(2006) Editorial: Seminars in Immunology 18:143‐144 |
21. Altered‐Balance: Inhibitory Ly49 receptors regulate NKG2D‐mediated NK cell functions
Malarkannan S
(2006) Seminars in Immunology 18:186‐192 |
22. NKG2D‐mediated NK cell Function is regulated by Inhibitory Ly49 Receptors
Regunathan J Chen Y, Wang D, and Malarkannan S
(2005) Blood 105:233‐240 |
23. Minor Histocompatibility Antigens: Time for a paradigm shift?
Malarkannan S
(2005) Transplantation Reviews 19:1‐19 |
24. Minor Histocompatibility Antigens: Molecular targets for immunomodulation in tissue
transplantation and tumor therapy
Malarkannan S, Regunathan J, and Tranchita AM
(2005) Clinical and Applied Immunology Reviews 5: 95‐109 |
25. Minor H Antigens: Molecular Barriers for successful Organ Transplantations
Malarkannan S, and Pooler LM
(2004) Ed: Drs D. Wilkes and W. Burlingham., in ‘Immunobiology of Organ Transplantation’, Chapter
7: 71‐105, Kluwer/Plenum Press. |
26. Unanticipated antigens: Translation initiation at CUG with leucine
Schwab SR, Shugart JA, Horng T, Malarkannan S, and Shastri N
(2004) PloS Biology 11:1774‐1784 |
27. A single amino acid polymorphism is the Emp‐3 gene defines immunodominant CTL responses
directed to the minor histocompatibility antigen, H4
Luedtke B, Tranchita A, Corbett R, Choi E Y, Roopenian D, and Malarkannan S
(2003) Immunogenetics 55: 284‐295 |
28. Minor Histocompatibility Antigens: Molecular Targets for Adoptive Cellular Immunotherapy
Malarkannan S
(2002) Current Opinion in Organ Transplantation 7:1‐12 |
29. Real‐time T cell Profiling Identifies H60 as a Major Minor Histocompatibility Antigen in Murine Graftvs‐
Host Disease
Choi E Y, Christianson G J, Malarkannan S, Joyce S, and Roopenian, D
(2002) Blood 100:4259‐4264 |
30. Quantitative analysis of the immune response to mouse non‐MHC transplantation antigens in vivo:
the H60 histocompatibility antigen, dominates over all others
Choi E Y, Christianson G J, Sproule T J, Yoshimura Y, Malarkannan S, Shastri N, Joyce S, Roopenian, D
(2001) J Immunol. 166: 4370‐4379 |
31. Generation and analysis of LacZ inducible T cell hybrids
Malarkannan S, Mendoza LM, and Shastri N
(2001) Methods Mol Biol. 156:265‐272 |
32. Identification of CD8+ T‐cell‐stimulating antigen genes in cDNA libraries
Mendoza LM, Malarkannan S, and Shastri N
(2001) Methods Mol Biol. 156:255‐63 |
33. Differences that matter: The major cytotoxic T cell stimulating minor histocompatibility antigens
Malarkannan S, Horng T, Eden P, Gonzalez F, Shih P, Brouwenstijn N, Roopenian D, and Shastri N
(2000) Immunity 13:333‐344 |
34. Presentation of out‐of‐frame peptide/MHC class I complexes by a novel translation initiation
mechanism
Malarkannan S, Horng T, Shih P, and Shastri N
(1999) Immunity, 10:681‐690 |
35. The Molecular and Functional Characterization of a dominant minor H antigen,
Malarkannan S, Shih P, Eden P, Horng T, Zuberi A, Christianson G, Roopenian D, and Shastri N
(1998) J Immunol. 161:3501‐3509 |
36. The mouse mammary tumor virus env gene is the source of a CD8+ T‐cell stimulating peptide
presented by a major histocompatibility complex class I molecule in a murine thymoma
Malarkannan S, Serwold T, Nguyen V, Sherman LA, and Shastri N
(1996) Proc Natl Acad Sci. (USA) 93:13991‐13996 |
37. Alloreactive CD8+ T‐cells can recognize unusual, rare, and unique processed peptide/MHC complexes
Malarkannan S, Gonzalez F, Nguyen V, Adair G, and Shastri N
(1996) J. Immunol. 157:4464‐4473 |
38. A rare cryptic translation product is presented by Kb major histocompatibility complex class I
molecule to alloreactive T‐cells
Malarkannan S, Afkarian M, Shastri N
(1995) J Exp Med. 182:1739‐1750 |
39. The role of MHC class I molecules in the generation of endogenous peptide/MHC complexes
Malarkannan S, Goth S, Buchholz DR, and Shastri N
(1995) J Immunol, 154: 585‐98 |
40. Immunodetection of biotinylated lymphocyte surface proteins by Enhanced Chemiluminescence ‐ a
non‐radioactive method for cell surface protein analysis
Meier T, Arni S, Malarkannan S, Poincelet M and Hoessli D C
(1992) Analytical Biochemistry 204: 220‐26 |
41. Impairment of Alternate pathway of T‐Cell Activation in leprosy
Malarkannan S, Chakkalath, H.R, and Muthukkaruppan VR
(1989) J Biosciences 14:29‐35 |
42. The Classical and Alternate Pathway of T‐cell activation in Leprosy
Muthukkaruppan VR, Chakkalath, H.R, and Malarkannan, S.
(1988) Immunology Letters 19:55‐60 |
43. Meier T, Arni S, Malarkannan S, Poincelet M, Hoessli D. Immunodetection of biotinylated lymphocyte-surface proteins by enhanced chemiluminescence: a nonradioactive method for cell-surface protein analysis. Anal Biochem. 1992 Jul;204(1):220-6. |
44. Milanovich S, Peterson J, Allred J, Stelloh C, Rajasekaran K, Fisher J, Duncan SA, Malarkannan S, Rao S. Sall4 overexpression blocks murine hematopoiesis in a dose-dependent manner. Exp Hematol. 2015 Jan;43(1):53-64.e1-8. PMCID: PMC4268405 |
45. Yea SS, So L, Mallya S, Lee J, Rajasekaran K, Malarkannan S, Fruman DA. Effects of novel isoform-selective phosphoinositide 3-kinase inhibitors on natural killer cell function. PLoS One. 2014;9(6):e99486. PMCID: PMC4051752 |
46. Abel AM, Schuldt KM, Rajasekaran K, Hwang D, Riese MJ, Rao S, Thakar MS, Malarkannan S. IQGAP1: insights into the function of a molecular puppeteer. Mol Immunol. 2015 Jun;65(2):336-49. PMCID: PMC4480615 |
47. Gerbec ZJ, Thakar MS, Malarkannan S. The Fyn-ADAP Axis: Cytotoxicity Versus Cytokine Production in Killer Cells. Front Immunol. 2015;6:472. PMCID: PMC4584950 |
48. Arumugam V, Bluemn T, Wesley E, Schmidt AM, Kambayashi T, Malarkannan S, Riese MJ. TCR signaling intensity controls CD8+ T cell responsiveness to TGF-β. J Leukoc Biol. 2015 Nov;98(5):703-12. PMCID: PMC4600064 |
49. Rajasekaran K, Riese MJ, Rao S, Wang L, Thakar MS, Sentman CL, Malarkannan S. Signaling in Effector Lymphocytes: Insights toward Safer Immunotherapy. Front Immunol. 2016;7:176. PMCID: PMC4863891 |
50. Li N, Xu W, Yuan Y, Ayithan N, Imai Y, Wu X, Miller H, Olson M, Feng Y, Huang YH, Jo Turk M, Hwang ST, Malarkannan S, Wang L. Author Correction: Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis. Sci Rep. 2018 Mar 01;8(1):4054. PMCID: PMC5832769 |
51. Jang Y, Gerbec ZJ, Won T, Choi B, Podsiad A, B Moore B, Malarkannan S, Laouar Y. Cutting Edge: Check Your Mice-A Point Mutation in the <i>Ncr1</i> Locus Identified in CD45.1 Congenic Mice with Consequences in Mouse Susceptibility to Infection. J Immunol. 2018 Mar 15;200(6):1982-1987. PMCID: PMC5840015 |
52. Xu W, Hiếu T, Malarkannan S, Wang L. The structure, expression, and multifaceted role of immune-checkpoint protein VISTA as a critical regulator of anti-tumor immunity, autoimmunity, and inflammation. Cell Mol Immunol. 2018 May;15(5):438-446. PMCID: PMC6068175 |
53. Nanbakhsh A, Best B, Riese M, Rao S, Wang L, Medin J, Thakar MS, Malarkannan S. Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells. J Vis Exp. 2018 Jan 15(131). PMCID: PMC5908645 |
54. Fisher JB, Peterson J, Reimer M, Stelloh C, Pulakanti K, Gerbec ZJ, Abel AM, Strouse JM, Strouse C, McNulty M, Malarkannan S, Crispino JD, Milanovich S, Rao S. The cohesin subunit Rad21 is a negative regulator of hematopoietic self-renewal through epigenetic repression of Hoxa7 and Hoxa9. Leukemia. 2017 Mar;31(3):712-719. PMCID: PMC5332284 |
55. Abel AM, Tiwari AA, Gerbec ZJ, Siebert JR, Yang C, Schloemer NJ, Dixon KJ, Thakar MS, Malarkannan S. IQ Domain-Containing GTPase-Activating Protein 1 Regulates Cytoskeletal Reorganization and Facilitates NKG2D-Mediated Mechanistic Target of Rapamycin Complex 1 Activation and Cytokine Gene Translation in Natural Killer Cells. Front Immunol. 2018;9:1168. PMCID: PMC5985319 |
56. Yang C, Tsaih SW, Lemke A, Flister MJ, Thakar MS, Malarkannan S. mTORC1 and mTORC2 differentially promote natural killer cell development. Elife. 2018 May 29;7. PMCID: PMC5976438 |
57. Wesley EM, Xin G, McAllister D, Malarkannan S, Newman DK, Dwinell MB, Cui W, Johnson BD, Riese MJ. Diacylglycerol kinase ζ (DGKζ) and Casitas b-lineage proto-oncogene b-deficient mice have similar functional outcomes in T cells but DGKζ-deficient mice have increased T cell activation and tumor clearance. Immunohorizons. 2018 Apr 01;2(4):107-118. PMCID: PMC6048965 |
58. Luo X, Chen J, Schroeder JA, Allen KP, Baumgartner CK, Malarkannan S, Hu J, Williams CB, Shi Q. Platelet Gene Therapy Promotes Targeted Peripheral Tolerance by Clonal Deletion and Induction of Antigen-Specific Regulatory T Cells. Front Immunol. 2018;9:1950. PMCID: PMC6136275 |
59. Abel AM, Yang C, Thakar MS, Malarkannan S. Natural Killer Cells: Development, Maturation, and Clinical Utilization. Front Immunol. 2018;9:1869. PMCID: PMC6099181 |
60. Yang C, Siebert JR, Burns R, Gerbec ZJ, Bonacci B, Rymaszewski A, Rau M, Riese MJ, Rao S, Carlson KS, Routes JM, Verbsky JW, Thakar MS, Malarkannan S. Heterogeneity of human bone marrow and blood natural killer cells defined by single-cell transcriptome. Nat Commun. 2019 Sep 02;10(1):3931. PMCID: PMC6718415 |
61. Liberio N, Robinson H, Nugent M, Simpson P, Margolis DA, Malarkannan S, Keever-Taylor C, Thakar MS. Single-center experience suggests donor lymphocyte infusion may promote long-term survival in children with high-risk acute lymphoblastic leukemia. Pediatr Blood Cancer. 2019 Nov;66(11):e27950. PMCID: PMC6754268 |
62. Xu W, Dong J, Zheng Y, Zhou J, Yuan Y, Ta HM, Miller HE, Olson M, Rajasekaran K, Ernstoff MS, Wang D, Malarkannan S, Wang L. Immune-Checkpoint Protein VISTA Regulates Antitumor Immunity by Controlling Myeloid Cell-Mediated Inflammation and Immunosuppression. Cancer Immunol Res. 2019 Sep;7(9):1497-1510. PMCID: PMC6726548 |
63. Reimer M Jr, Pulakanti K, Shi L, Abel A, Liang M, Malarkannan S, Rao S. Deletion of Tet proteins results in quantitative disparities during ESC differentiation partially attributable to alterations in gene expression. BMC Dev Biol. 2019 Jul 08;19(1):16. PMCID: PMC6615237 |
64. Kumar P, Rajasekaran K, Nanbakhsh A, Gorski J, Thakar MS, Malarkannan S. IL-27 promotes NK cell effector functions via Maf-Nrf2 pathway during influenza infection. Sci Rep. 2019 Mar 21;9(1):4984. PMCID: PMC6428861 |
65. Rajasekaran K, Kumar P, Schuldt KM, Peterson EJ, Vanhaesebroeck B, Dixit V, Thakar MS, Malarkannan S. Erratum: Signaling by Fyn-ADAP via the carma1-Bcl-10-MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells (Nature Immunology (2013) DOI 10.1038/ni2708)) Nature Immunology. February 2014;15(2):205. |
66. Malarkannan S. Missing-self: Revisited Seminars in Immunology. June 2006;18(3):143-144. |
67. Malarkannan S, Regunathan J, Timler AM. Minor histocompatibility antigens: Molecular targets for immunomodulation in tissue transplantation and tumor therapy Clinical and Applied Immunology Reviews. March 2005;5(2):95-109. |
68. Malarkannan S. Minor histocompatibility antigens: Time for a paradigm shift? Transplantation Reviews. January 2005;19(1):1-19. |
69. Malarkannan S. Minor histocompatibility antigens: Molecular targets for adoptive cellular immunotherapy Current Opinion in Organ Transplantation. September 2002;7(3):299-304. |
70. Malarkannan S, Chakkalath HR, Muthukkaruppan VR. Impairment of alternate pathway (CD2) of T cell activation in leprosy Journal of Biosciences. March 1989;14(1):29-36. |
71. Rajasekaran K, Kumar P, Schuldt KM, Peterson EJ, Vanhaesebroeck B, Dixit V, Thakar MS, Malarkannan S. Corrigendum: Signaling by Fyn-ADAP via the Carma1-Bcl-10-MAP3K7 signalosome exclusively regulates inflammatory cytokine production in NK cells. Nat Immunol. 2014 Jan 21;15(2):205. |
72. Li N, Xu W, Yuan Y, Ayithan N, Imai Y, Wu X, Miller H, Olson M, Feng Y, Huang YH, Jo Turk M, Hwang ST, Malarkannan S, Wang L. Immune-checkpoint protein VISTA critically regulates the IL-23/IL-17 inflammatory axis. Sci Rep. 2017 May 03;7(1):1485. PMCID: PMC5431161 |
73. Sitaram P, Uyemura B, Malarkannan S, Riese MJ. Beyond the cell surface: Targeting intracellular negative regulators to enhance t cell anti-tumor activity International Journal of Molecular Sciences. 1 December 2019;20(23). |
74. Schloemer NJ, Abel AM, Thakar MS, Malarkannan S. In Vivo Assessment of NK Cell-Mediated Cytotoxicity by Adoptively Transferred Splenocyte Rejection. Methods Mol Biol. 2020;2097:115-123. |
75. Nanbakhsh A, Malarkannan S. Dextran Enhances the Lentiviral Transduction Efficiency of Murine and Human Primary NK Cells. Methods Mol Biol. 2020;2097:107-113. |
76. Chen Y, Yang M, Huang W, Chen W, Zhao Y, Schulte ML, Volberding P, Gerbec Z, Zimmermann MT, Zeighami A, Demos W, Zhang J, Knaack DA, Smith BC, Cui W, Malarkannan S, Sodhi K, Shapiro JI, Xie Z, Sahoo D, Silverstein RL. Mitochondrial Metabolic Reprogramming by CD36 Signaling Drives Macrophage Inflammatory Responses. Circ Res. 2019 Dec 06;125(12):1087-1102. PMCID: PMC6921463 |
77. Nanbakhsh A, Srinivasamani A, Holzhauer S, Riese MJ, Zheng Y, Wang D, Burns R, Reimer MH, Rao S, Lemke A, Tsaih SW, Flister MJ, Lao S, Dahl R, Thakar MS, Malarkannan S. <i>Mirc11</i> Disrupts Inflammatory but Not Cytotoxic Responses of NK Cells. Cancer Immunol Res. 2019 Oct;7(10):1647-1662. PMCID: PMC7428857 |
78. Sitaram P, Uyemura B, Malarkannan S, Riese MJ. Beyond the Cell Surface: Targeting Intracellular Negative Regulators to Enhance T cell Anti-Tumor Activity. Int J Mol Sci. 2019 Nov 20;20(23). PMCID: PMC6929154 |
79. Thakar MS, Kearl TJ, Malarkannan S. Controlling Cytokine Release Syndrome to Harness the Full Potential of CAR-Based Cellular Therapy. Front Oncol. 2019;9:1529. PMCID: PMC7006459 |
80. Yang C, Siebert JR, Burns R, Zheng Y, Mei A, Bonacci B, Wang D, Urrutia RA, Riese MJ, Rao S, Carlson KS, Thakar MS, Malarkannan S. Single-cell transcriptome reveals the novel role of T-bet in suppressing the immature NK gene signature. Elife. 2020 May 14;9. PMCID: PMC7255804 |
81. Wang D, Malarkannan S. Transcriptional Regulation of Natural Killer Cell Development and Functions. Cancers (Basel). 2020 Jun 16;12(6). PMCID: PMC7352776 |
82. Hashemi E, Malarkannan S. Tissue-Resident NK Cells: Development, Maturation, and Clinical Relevance. Cancers (Basel). 2020 Jun 12;12(6). PMCID: PMC7352973 |
83. Idso JM, Lao S, Schloemer NJ, Knipstein J, Burns R, Thakar MS, Malarkannan S. Entinostat augments NK cell functions via epigenetic upregulation of IFIT1-STING-STAT4 pathway. Oncotarget. 2020 May 19;11(20):1799-1815. PMCID: PMC7244011 |
84. Yang C, Malarkannan S. Transcriptional Regulation of NK Cell Development by mTOR Complexes. Front Cell Dev Biol. 2020;8:566090. PMCID: PMC7683515 |
85. Malarkannan S. Molecular mechanisms of FasL-mediated 'reverse-signaling'. Mol Immunol. 2020 Nov;127:31-37. PMCID: PMC7606657 |
86. Gerbec ZJ, Hashemi E, Nanbakhsh A, Holzhauer S, Yang C, Mei A, Tsaih SW, Lemke A, Flister MJ, Riese MJ, Thakar MS, Malarkannan S. Conditional Deletion of PGC-1α Results in Energetic and Functional Defects in NK Cells. iScience. 2020 Sep 25;23(9):101454. PMCID: PMC7474003 |
87. Malarkannan S. NKG7 makes a better killer. Nat Immunol. 2020 Oct;21(10):1139-1140. |
88. Malarkannan S. Molecular mechanisms of FasL-mediated 'reverse-signaling'. Mol Immunol. 2020 Nov;127:31-37. PMCID: PMC7606657 |
89. Nanbakhsh A, Malarkannan S. The Role of microRNAs in NK Cell Development and Function. Cells. 2021 Aug 07;10(8). PMCID: PMC8391642 |
90. Khalil M, Wang D, Hashemi E, Terhune SS, Malarkannan S. Implications of a 'Third Signal' in NK Cells. Cells. 2021 Jul 31;10(8). PMCID: PMC8393955 |
91. Hashemi E, Bjorgaard S, Wang D, Uyemura B, Riese M, Thakar MS, Malarkannan S. NK Cell Development and Function in Patients with Fanconi Anemia. Crit Rev Immunol. 2021;41(2):35-44. PMCID: PMC11536512 |
92. Wang D, Uyemura B, Hashemi E, Bjorgaard S, Riese M, Verbsky J, Thakar MS, Malarkannan S. Role of GATA2 in Human NK Cell Development. Crit Rev Immunol. 2021;41(2):21-33. PMCID: PMC11536496 |
93. Dixon KJ, Siebert JR, Wang D, Abel AM, Johnson KE, Riese MJ, Terhune SS, Tarakanova VL, Thakar MS, Malarkannan S. MyD88 is an essential regulator of NK cell-mediated clearance of MCMV infection. Mol Immunol. 2021 Sep;137:94-104. |
94. Malarkannan S. Molecular mechanisms of FasL-mediated 'reverse-signaling'. Mol Immunol. 2020 Nov;127:31-37. PMCID: PMC7606657 |
95. Wang D, Malarkannan S. Transcriptomic perspectives of memory-like NK cells and aging. Genome Med. 2022 May 25;14(1):57. PMCID: PMC9129893 |
96. Khalil M, Mei A, Hashemi E, Wang D, Schumacher M, Terhune S, Malarkannan S. Method to Study Adaptive NK Cells Following MCMV Infections. Methods Mol Biol. 2022;2463:195-204. |
97. Hashemi E, Mei A, Wang D, Khalil M, Malarkannan S. Methods for Isolating and Defining Single-Cell Transcriptomes of Tissue-Resident Human NK Cells. Methods Mol Biol. 2022;2463:103-116. |
98. Mei A, Hashemi E, Khalil M, Wang D, Malarkannan S. Isolation of Innate Lymphoid Cells from Murine Intestinal Lamina Propria. Methods Mol Biol. 2022;2463:3-9. |
99. Wang D, Burns R, Khalil M, Mei A, Hashemi E, Malarkannan S. Methods to Analyze the Developmental Trajectory of Human Primary NK Cells Using Monocle and SCENIC Analyses. Methods Mol Biol. 2022;2463:81-102. |
100. Gerbec Z, Malarkannan S. NK cell-mediated immunotherapy: The exquisite role of PGC-1a in metabolic reprogramming Successes and Challenges of NK Immunotherapy: Breaking Tolerance to Cancer Resistance. 1 January 2021:121-142. |
101. Khalil M, Malarkannan S. Innatus immunis: Evolving paradigm of adaptive NK cells. J Exp Med. 2022 Nov 07;219(11). PMCID: PMC9449531 |
102. Kaur K, Chen PC, Ko MW, Mei A, Chovatiya N, Huerta-Yepez S, Ni W, Mackay S, Zhou J, Maharaj D, Malarkannan S, Jewett A. The Potential Role of Cytotoxic Immune Effectors in Induction, Progression and Pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Cells. 2022 Oct 31;11(21). PMCID: PMC9656116 |
103. Kaur K, Chen PC, Ko MW, Mei A, Huerta-Yepez S, Maharaj D, Malarkannan S, Jewetta A. Successes and challenges in taming the beast: Cytotoxic immune effectors in amyotrophic lateral sclerosis Critical Reviews in Immunology. 2023;43(1):1-11. |
104. Kaur K, Chen PC, Ko MW, Mei A, Senjor E, Malarkannan S, Kos J, Jewett A. Sequential therapy with supercharged NK cells with either chemotherapy drug cisplatin or anti-PD-1 antibody decreases the tumor size and significantly enhances the NK function in Hu-BLT mice. Front Immunol. 2023;14:1132807. PMCID: PMC10183580 |
105. Hashemi E, McCarthy C, Rao S, Malarkannan S. Transcriptomic diversity of innate lymphoid cells in human lymph nodes compared to BM and spleen. Commun Biol. 2024 Jun 25;7(1):769. PMCID: PMC11199704 |
106. George B, Kudryashova O, Kravets A, Thalji S, Malarkannan S, Kurzrock R, Chernyavskaya E, Gusakova M, Kravchenko D, Tychinin D, Savin E, Alekseeva L, Butusova A, Bagaev A, Shin N, Brown JH, Sethi I, Wang D, Taylor B, McFall T, Kamgar M, Hall WA, Erickson B, Christians KK, Evans DB, Tsai S. Transcriptomic-Based Microenvironment Classification Reveals Precision Medicine Strategies for Pancreatic Ductal Adenocarcinoma. Gastroenterology. 2024 May;166(5):859-871.e3. |
107. Kumar P, Rajasekaran K, Malarkannan S. Novel PI(3)K-p85α/p110δ-ITK-LAT-PLC-γ2 and Fyn-ADAP-Carma1-TAK1 Pathways Define Reverse Signaling via FasL. Crit Rev Immunol. 2024;44(1):55-77. |
108. Kaur K, Chen PC, Ko MW, Mei A, Huerta-Yepez S, Maharaj D, Malarkannan S, Jewett A. Successes and Challenges in Taming the Beast: Cytotoxic Immune Effectors in Amyotrophic Lateral Sclerosis. Crit Rev Immunol. 2023;43(1):1-11. |
109. Chen V, Zhang J, Chang J, Beg MA, Vick L, Wang D, Gupta A, Wang Y, Zhang Z, Dai W, Kim M, Song S, Pereira D, Zheng Z, Sodhi K, Shapiro JI, Silverstein RL, Malarkannan S, Chen Y. CD36 restricts lipid-associated macrophages accumulation in white adipose tissues during atherogenesis. Front Cardiovasc Med. 2024;11:1436865. PMCID: PMC11327822 |
110. Lauener MP, Tanaka E, Mei A, Abdossamadi S, Ostroumov E, Geltink RIK, Malarkannan S, Schultz KR. Expansion and characterization of immune suppressive CD56(bright)Perforin(-) regulatory-like natural killer cells in chronic graft-versus-host disease. Cytotherapy. 2024 Dec;26(12):1472-1483. |
111. Lella RK, Malarkannan S. IQGAP1 promotes early B cell development, is essential for the development of marginal zone (MZ) B cells, and is critical for both T-dependent and T-independent antibody responses. Cell Mol Life Sci. 2024 Nov 25;81(1):462. PMCID: PMC11589066 |
112. Huerta-Yepez S, Chen PC, Kaur K, Jain Y, Singh T, Esedebe F, Liao YJ, DiBernardo G, Moatamed NA, Mei A, Malarkannan S, Graeber TG, Memarzadeh S, Jewett A. Supercharged NK cells, unlike primary activated NK cells, effectively target ovarian cancer cells irrespective of MHC-class I expression. BMJ Oncol. 2025;4(1):e000618. PMCID: PMC11973776 |
113. Ko MW, Mei A, Senjor E, Nanut MP, Gao LW, Wong P, Chen PC, Cohn W, Whitelegge JP, Kos J, Kaur K, Malarkannan S, Jewett A. Osteoclast-expanded supercharged NK cells perform superior antitumour effector functions. BMJ Oncol. 2025;4(1):e000676. PMCID: PMC12161327 |
114. George J, Ma X, Kadamberi IP, Nair A, Mittal S, Hashemi E, Kumar S, Singh M, Geethadevi A, Pradeep M, Nair A, Tsaih SW, Jorns JM, Malarkannan S, Dietlein F, Lin CW, Pradeep S, Chaluvally-Raghavan P. Single-cell transcriptomics reveals FXR1 as an actionable target for siRNA therapy in ovarian cancer. Nat Commun. 2026 Apr 03;17(1). PMCID: PMC13219712 |
115. Mammoto T, Kyi P, Scheer M, Hunyenyiwa T, Hashemi E, Ma X, Turner CE, Lin CW, Malarkannan S, Mammoto A. Paxillin in mechanosensitive spatial control of lung endothelial cell regeneration. NPJ Regen Med. 2026 May 18. |
